Figure 3
From: The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer
GCNT1 promotes prostate tumour growth in vivo. (A) Knockdown of GCNT1 using shRNA significantly reduces the growth of CWR22RV1 tumours xenografts in a subcutaneous xenograft model. (B) Upregulation of GCNT1 in PC3 cells significantly increases the growth of subcutaneous xenograft tumours. (C) Knockdown of GCNT1 significantly reduces the adhesion of CWR22RV1 cells to collagen and fibronectin coated plates, whereas overexpression of GCNT1 in PC3 cells has the opposite effect.
